Denosumab combined with immunotherapy, radiotherapy, and granulocyte-macrophage colony-stimulating factor for the treatment of metastatic nasopharyngeal carcinoma: A case report

Figure 2 Treatment. A: The target area of the patient was irradiated by three radiation treatments during the PRaG 2.0X treatment; B: PRaG 2.0X treatment process. The patient received three cycles of RANKL inhibitor combined with radiotherapy and immunotherapy and 15 cycles of RANKL inhibitor combined with immunotherapy for consolidation therapy, including multiple imaging evaluations; C: The entire diagnosis and treatment process of the patient since being diagnosed with nasopharyngeal carcinoma. PD-1: Programmed cell death protein 1; PD-L1: Programmed death receptor-ligand 1; IL: Interleukin; GM-CSF: Granulocyte-macrophage colony-stimulating factor.